Clinical trial
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular…
NCT00104728 · H. Lee Moffitt Cancer Center and Research Institute, Other · Terminated
Key facts
| NCT number | NCT00104728 |
|---|---|
| Title | Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates |
| Official title | Pilot Neoadjuvant Study of ZD1839 (IRESSA®) as Single Agent Preoperative Therapy for Clinical Stage 1A and 1B (T1-2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC) With Molecular Correlates |
| Lead sponsor | H. Lee Moffitt Cancer Center and Research Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH AstraZeneca Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | ZD1839 |
| Enrollment | 42 |
| Start date | Oct 1, 2004 |
| Primary completion | May 1, 2008 |
| Completion | Mar 1, 2009 |
| First posted | Mar 4, 2005 |
| Last update posted | Oct 31, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: